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Introduction
The coronavirus disease 2019 (COVID19) pandemic has created a global health
crisis, which requires effective prevention and treatment strategies on an unprecedented scale. The development of
COVID-19 vaccines in the current and
planned clinical trials is essential for the
success of this public health response,
which should be supported strongly by
all physicians. This paper focuses on how
physicians should implement the results
of clinical trials when counseling patients who are pregnant, planning to
become pregnant, breastfeeding, or
planning to breastfeed about vaccines.
In December 2020, the US Food and
Drug Administration (FDA) issued an
Emergency Use Authorization (EUA) for
the following 2 vaccines for the
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The development of coronavirus disease 2019 vaccines in the current and planned
clinical trials is essential for the success of a public health response. This paper
focuses on how physicians should implement the results of these clinical trials
when counseling patients who are pregnant, planning to become pregnant,
breastfeeding or planning to breastfeed about vaccines with government authorization for clinical use. Determining the most effective approach to counsel patients
about coronavirus disease 2019 vaccination is challenging. We address the professionally responsible counseling of 3 groups of patients—those who are pregnant, those planning to become pregnant, and those breastfeeding or planning to
breastfeed. We begin with an evidence-based account of the following 5 major
challenges: the limited evidence base, the documented increased risk for severe
disease among pregnant coronavirus disease 2019-infected patients, conflicting
guidance from government agencies and professional associations, false information about coronavirus disease 2019 vaccines, and maternal mistrust and
vaccine hesitancy. We subsequently provide evidence-based, ethically justified,
practical guidance for meeting these challenges in the professionally responsible
counseling of patients about coronavirus disease 2019 vaccination. To guide the
professionally responsible counseling of patients who are pregnant, planning to
become pregnant, and breastfeeding or planning to breastfeed, we explain how
obstetrician-gynecologists should evaluate the current clinical information, why a
recommendation of coronavirus disease 2019 vaccination should be made, and
how this assessment should be presented to patients during the informed consent
process with the goal of empowering them to make informed decisions. We also
present a proactive account of how to respond when patients refuse the recommended vaccination, including the elements of the legal obligation of informed
refusal and the ethical obligation to ask patients to reconsider. During this process,
the physician should be alert to vaccine hesitancy, ask patients to express their
hesitation and reasons for it, and respectfully address them. In contrast to the
conflicting guidance from government agencies and professional associations,
evidence-based professional ethics in obstetrics and gynecology provides unequivocal and clear guidance: Physicians should recommend coronavirus disease
2019 vaccination to patients who are pregnant, planning to become pregnant, and
breastfeeding or planning to breastfeed. To prevent widening of the health inequities, build trust in the health benefits of vaccination, and encourage coronavirus disease 2019 vaccine and treatment uptake, in addition to recommending
coronavirus disease 2019 vaccinations, physicians should engage with communities to tailor strategies to overcome mistrust and deliver evidence-based information, robust educational campaigns, and novel approaches to immunization.
Key words: autonomy, becoming pregnant, beneficence, breastfeeding, clinical trials,
counseling, COVID-19, informed consent, informed refusal, mRNA vaccines, pregnancy,
professional ethics, SARS-CoV-2, shared decision-making, vaccination
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prevention of COVID-19: the PﬁzerBioNtech vaccine for persons aged 16
years and the Moderna vaccine for persons aged 18 years.1
The EUA states that children and adolescents outside of these authorized age
groups should not receive a COVID-19
vaccination at this time.
The US Centers for Disease Control
and Prevention (CDC) mentions severe
and immediate allergic reactions to a
previous dose of a messenger RNA
(mRNA) COVID-19 vaccine, its components, or to polysorbate as contraindications.1 These individuals should not
receive an mRNA COVID-19 vaccination at this time unless they have been
evaluated by an allergist-immunologist
and it has been established that the individual can safely receive the vaccine.1
Pregnancy, attempting to become
pregnant, and breastfeeding have not
been deemed as contraindications for
the mRNA vaccines, and the CDC stated
that “. . . if pregnant people are part of a
group that is recommended to receive a
COVID-19 vaccine (e.g., healthcare
personnel), they may choose to be
vaccinated.”1
American College of Obstetricians
and Gynecologists (ACOG) recommends that COVID-19 vaccines should
not be withheld from pregnant patients
who meet the criteria for vaccination
based on the recommended priority
groups determined by the Advisory
Committee on Immunization Practices
(ACIP).2 COVID-19 vaccines should be
offered to lactating patients similar to
nonlactating patients when they meet
the criteria for receipt of the vaccine
based on prioritization groups outlined
by the ACIP.3
ACOG also stated that those “. . .
considering a COVID-19 vaccine should
have access to available information
about the safety and efﬁcacy of the vaccine, including information about data
that are not available. A conversation
between the patient and their clinical
team may assist with decisions regarding
the use of vaccines approved under EUA
for the prevention of COVID-19 by
pregnant patients.”2
Determining the most effective
approach for this conversation is
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challenging. In this clinical opinion, we
identiﬁed 5 major challenges and provide evidence-based, ethically justiﬁed,
practical guidance for overcoming these
challenges when counseling patients
about COVID-19 vaccinations. Our aim
was to be both clinically applicable and
sensitive to the patients’ concerns. We
therefore addressed the counseling of 3
groups of patientseethose who are
pregnant, those planning to become
pregnant, and those breastfeeding or
planning to breastfeed.

Challenges With Counseling Patients
There currently is insufﬁcient evidence
from clinical trials about the safety and
efﬁcacy of the COVID-19 vaccines in
pregnancy because pregnant women
have been excluded from these vaccine
trials. The theoretical risk of the COVID19 vaccine must be assessed in the
context of the documented increased
risk for a severe COVID-19 disease
course in pregnant women and their fetuses.4 Immunization with inactivated
virus vaccines or toxoids during pregnancy is not expected to be associated
with an increased risk to the pregnant
patient or the fetus.5,6 In an overview of
17 systematic reviews reporting on
maternal-fetal and neonatal outcomes
after immunizations during pregnancy,
no major safety concerns and risks were
identiﬁed for any of the vaccines or
outcomes of interest.7 Statements from
governments and professional associations regarding vaccination during
pregnancy are inconsistent; false information and rumors abound. Some patients hesitate to become vaccinated,
whereas others refuse vaccination.
Limited evidence base
Counseling pregnant patients about the
efﬁcacy and safety of COVID-19 vaccinations confronts the challenge that the
clinical trials for the vaccines currently
available excluded pregnant patients.
Pregnant women are commonly
excluded from vaccine and drug trials. A
contributing reason for this exclusion is
likely legal in nature instead of ethical in
that vaccine and drug manufacturers
might expose themselves to liabilities of
injury to fetuses and future children that
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was allegedly caused by the administration of a vaccine or drug as a subject in a
clinical trial. Vaccine and drug manufacturers have a corporate interest in
preventing such a liability. This obstacle
could be removed by legislation
addressing clinical trial participation,
which is long overdue. Such a policy
change, however, is unlikely to occur
soon enough for the inclusion of pregnant patients in ongoing or new
COVID-19 vaccine trials.
The exclusion of pregnant patients
from clinical vaccine trials causes there
to be a lack of data from a clinical trial
arm that would provide trial-based evidence for assessing both the efﬁcacy and
safety of COVID-19 vaccinations in
pregnant patients and their offspring. To
date, there are no efﬁcacy or safety data
speciﬁcally for the use of COVID-19
mRNA vaccines during pregnant or in
lactating patients. Therefore, based on
the absence of actual trial data, the risks
to pregnant and fetal patients are unknown. There is, however, a large database of direct evidence on the potential
safety of nonliving virus vaccines from
the past experiences of subjects in the
treatment arms of trials. There is also
indirect evidence. The mRNA vaccines
are nonliving virus vaccines. These do
not use an adjuvant to enhance the vaccine efﬁcacy. In addition, mRNA vaccines do not enter the nucleus and do not
alter human DNA in the vaccine recipients. Therefore, “. . . the mRNA
strand never enters the cell’s nucleus or
affects genetic material. . . .”8 It is also
unlikely that the mRNA will cross the
placenta. In studies on mice vaccinated
against the Zika virus, mRNA was shown
to protect against placental damage.9
This evidence suggests that the probable hypothesis about the use of the
current nonliving COVID-19 virus vaccines in pregnant patients is that these
are safe and efﬁcacious. The CDC states
that “. . . based on current knowledge,
experts believe that mRNA vaccines are
unlikely to pose a risk to the pregnant
person or the fetus. . . .”1 Clinical trials
that include pregnant patients are
needed to test this hypothesis. The FDA
now encourages developers of COVID19 vaccines to consider programs that
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might support the inclusion of pregnant
subjects and subjects of childbearing
potential to not avoid pregnancy early
during the development.10 For example,
contrary to the current EUA approved
vaccines, which excluded pregnant patients from their trials, the ongoing
AZD1222 COVID-19 vaccine study does
not speciﬁcally exclude pregnant
subjects.
Documented increased risk of severe
disease among pregnant coronavirus
disease 2019 infected patients
Pregnant patients, especially those with
comorbidities, are considered to be a
higher-risk group for COVID-19 infection.11,12 These patients are not more
likely to become infected and the majority of pregnant patients have mild or
asymptomatic infections. However,
there are reports of a more severe disease
course and other pregnancy complications if pregnant patients become
infected.13e19 There is therefore an
increased potential for maternal
deaths,20e23 especially in low- to middleincome countries.24 There are also
disparate accounts of an increase in
premature births,23,25e27 premature cesarean deliveries,28 and myocardial injuries29,30 in addition to an increased risk
for preeclampsia, cesarean delivery, and
perinatal death in pregnant women with
COVID-19
infections.31
When
compared with COVID-19 infected,
nonpregnant peers, symptomatic pregnant patients may be at an increased risk
for a more severe COVID-19 disease
course.32 Kim et al33 reported an
increased case fatality rate among
critically ill pregnant patients, although
there is variable information on the
rate of intensive care unit (ICU) admissions for pregnant COVID-19 patients.25,34,35 Vertical transmission of
severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) from the
mother to the fetus has also been reported.36,37 In addition, COVID-19
infections have been associated with
increased placental inﬂammation and
histopathologic abnormalities, fetal
vascular malperfusion, and villitis,
suggesting that the virus could impact
perinatal outcomes through placental

injury with possible adverse effects in
the neonates.38,39
Black and Hispanic patients seem to
be disproportionately more affected by
SARS-CoV-2 infections, not only during
pregnancy, and have an increased risk for
admission to the ICU and receipt of
mechanical ventilation, but not an
increased risk for death.32,40e42 Finally,
Saccone et al43 reported that among
pregnant women, more than half of the
respondents rated the psychological
impact of the COVID-19 outbreak as
severe and about two-thirds reported
higher than normal anxiety.
Conﬂicting guidance from government
agencies and professional associations
International government agencies and
professional associations in Asia,
Europe, the Middle East, and North
America, and the World Health Organization (WHO) take different positions
on the vaccination of pregnant patients
(Table 1). The positions differ both on
scientiﬁc and ethical grounds.
Some take an approach based on the
ethical principle of respect for autonomy
(Table 2). The CDC in the United States
appeals implicitly to this ethical principle in the sense that information should
be provided and the patients’ questions
should be addressed, but no recommendations are made.1 The ACOG takes
a similar position.2
Canada47 and Ireland51 state that the
physician should explain that the risk to
beneﬁt ratio favors vaccination and that
it should be offered. These positions assume that a vaccination is not contraindicated for pregnancy and that the
clinical beneﬁts outweigh the risks. The
precautionary principle is not violated
(Table 2). Therefore, according to these 2
recommendations, patients should
decide for themselves without a recommendation being made.
Others take beneﬁcence-based approaches and come to different conclusions (Table 2). Austria48 states that
vaccination is contraindicated for pregnancy and breastfeeding patients and
that vaccination of the partners of
pregnant patients should be a priority.
France,49 The Netherlands,53 and
Japan55 take the position that

vaccination should not be recommended
for use during pregnancy. These positions assume that the risk to beneﬁt ratio
of the vaccination of pregnant patients is
unfavorable and that it violates the precautionary principle.
In contrast, Germany50 and The
United Kingdom52 take the position that
vaccination should be offered only after a
risk assessment. This position assumes
that the risk to beneﬁt ratio is favorable
and therefore that the precautionary
principle is not violated. The current
evidence base supports the recommendation of vaccines. Israel states that “. . .
priority will now be given to breastfeeding women, pregnant women and
women who are planning to get
pregnant.”54
The WHO56 takes the position that
there are insufﬁcient data to provide
guidance. Guidance should be delayed
until the evidence base permits a more
deﬁnitive assessment of the risk to
beneﬁt ratio. This position invokes the
precautionary principle to manage
uncertainty.
False information about coronavirus
disease 2019 vaccinations
It is a disturbing reality that there is an
abundance of false information available
on the internet and provided by prominent public ﬁgures about vaccine use in
general and in women speciﬁcally. For
example, although there have been unfounded allegations of risks of infertility
from COVID-19 vaccinations mainly on
antivaccination blogs and websites and
posted to social media,57 the American
Society for Reproductive Medicine
(ASRM) published clinical recommendations debunking the myths of a potential impact of COVID-19 vaccination
on fertility.46 The ASRM encourages
COVID-19 vaccination for those undergoing fertility treatment and pregnant and lactating patients according to
the eligibility criteria.46
Maternal mistrust and vaccine
hesitancy
The inﬂuence of personal beliefs,
mistrust among disenfranchised populations, and experiences with antenatal
vaccination uptake is exacerbated during
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TABLE 1

Guidance from governments and professional associations
North American
United States: The United States Centers for Disease Control (CDC) states: “People who are pregnant and part of a group recommended to receive
the COVID-19 vaccine may choose to be vaccinated. If they have questions about getting vaccinated, a discussion with a healthcare provider might
help them make an informed decision.”1,44
The American College of Obstetricians and Gynecologists states that: “COVID-19 vaccines should not be withheld from pregnant individuals who
meet criteria for vaccination based on ACIP-recommended priority groups.” And they also state that “COVID-19 vaccines should be offered to
lactating individuals similar to nonlactating individuals when they meet criteria for receipt of the vaccine based on prioritization groups outlined by
the ACIP.”2
The Society for Maternal-Fetal Medicine (SMFM) states that: “. . . SMFM recommends that healthcare workers, who are considered prioritized for
vaccination, be offered the vaccine if pregnant. . . .” And they also state that “. . . pregnant and lactating women who are otherwise eligible should be
offered the vaccine.”45
The American Society for Reproductive Medicine states that: “Patients undergoing fertility treatment and pregnant patients should be encouraged to
receive vaccination based on eligibility criteria. Since the vaccine is not a live virus, there is no reason to delay pregnancy attempts because of
vaccination administration or to defer treatment until the second dose has been administered. . . .” And they state, “A shared decision-making model
between patients and providers should be used when considering vaccination and should take into consideration the ethical principles of autonomy,
beneficence, and nonmaleficence.”46
Canada: The Canadian Society of Obstetricians and Gynecologists of Canada (SOGC) states: “For individuals who are at high risk of infection and/or
morbidity from COVID-19, it is the SOGC’s position that the documented risk of not getting the COVID-19 vaccine outweighs the theorized and
undescribed risk of being vaccinated during pregnancy or while breastfeeding and vaccination should be offered.”47
Europe
Austria: The health ministry has said that COVID vaccination is contraindicated in pregnant and breastfeeding women but priority for immunization
should be given to partners of pregnant women because of the severe disease history in pregnancy.48
France: The health ministry states: “Administration of the vaccine during pregnancy is not recommended (unless a high risk of severe form
was identified during the prevaccination consultation), the safety data still being insufficient to inform about the risks of vaccination during
pregnancy. . . .”49
Germany: the Robert Koch institute states: “. . . because there is insufficient experience, immunization in pregnancy and while breastfeeding is
currently only recommended after individual risk-benefit assessment.”50
Ireland: The Royal College of Physicians of Ireland states: “Pregnant healthcare workers are numerous in our workforce and their specific needs
should be considered equally alongside their nonpregnant colleagues. Assessment of risk by the individual needs acknowledgment, and the
pregnant woman should be able to choose vaccination if she falls into a priority group. Counseling by healthcare provider should balance available
data on vaccine safety, risks to pregnant women from COVID-19 infection, and a woman’s individual risk for infection and severe disease. While
there is no data on breastfeeding, there is no known biologic mechanism to cause harm.”51
United Kingdom: The Joint Committee on Vaccination and Immunization (JCVI), which previously said that pregnant women should not be
immunized, now says (as of December 30, 2020) that: “Although the available data do not indicate any safety concern or harm to pregnancy, there is
insufficient evidence to recommend routine use of COVID-19 vaccines during pregnancy,” and they state that “. . . the JCVI now advises that if a
pregnant woman meets the definition of being clinically extremely vulnerable, then she should discuss the options of COVID-19 vaccination with her
obstetrician and/or doctor. This is because their underlying condition may put them at very high risk of experiencing serious complications of COVID19.”52
The Netherlands: The National Institute for Public Health and the Environment of the Ministry of Health, Welfare, and Sport states: “Are you
pregnant? If so, it is recommended to postpone the vaccination until after your pregnancy.”53
Middle East
Israel: “Priority will now be given to breastfeeding women, pregnant women and women who are planning to get pregnant.”54
Asia
Japan: “Pregnant women will not be given vaccination priority due to insufficient knowledge about vaccine safety and effectiveness for them.”55
International
The World Health Organization states that, “.those pregnant women at high risk of exposure to SARS-CoV-2 (e.g. health workers) or who have
comorbidities which add to their risk of severe disease, may be vaccinated in consultation with their health care provider.”56
ACIP, Advisory Committee on Immunization Practices; COVID-19, coronavirus disease 2019.
Chervenak. Counseling patients about coronavirus disease 2019 vaccination. Am J Obstet Gynecol 2021.
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TABLE 2

Ethical principles
Beneficence: Creates the ethical obligation to provide clinical management that in deliberative
(evidence-based, rigorous, transparent, and accountable) clinical judgment is predicted to
result in a net clinical benefit for the patient.50
Respect for autonomy: Creates the ethical obligation to empower patients to make informed
and voluntary decisions about the clinical management of their condition by providing them
with information about the clinical management supported in beneficence-based clinical
judgment.49
Precautionary: A “longstanding principle of public health: when in doubt about danger, we
should err on the side of caution” by preventing danger.57
Chervenak. Counseling patients about coronavirus disease 2019 vaccination. Am J Obstet Gynecol 2021.

pandemic periods. Although the acceptance of vaccination should be a global
norm, inﬂuences by historic, economic,
or political factors can lead to vaccine
hesitancy, for example the history of
mistreatment of women of color in the
United States. Vaccine hesitancy refers to
the delay in acceptance or refusal of
vaccinations despite the availability of
vaccination services.58

The Informed Consent Process
Professional ethics in obstetrics and gynecology59,60,61 provide practical tools to
meet the challenges of counseling the
following 3 groups of patients whom the
obstetrician-gynecologist will encounter
in clinical practice: those who are pregnant, plan to become pregnant, and
those who are breastfeeding or planning
to do so. The informed consent process
implements the ethical principle of
respect for autonomy, which calls for the
obstetrician-gynecologist to empower
patients with the information that they
need to make informed decisions. The
role of the physician in the informed
consent process is to identify the clinically relevant information and assess it in
an evidence-based clinical judgment,
present this information and assessment
to the patient, and explain the physician’s
evaluation. These steps empower patients to make informed decisions.
The informed consent process empowers the patient to make informed
decisions when that process is based on
her values and beliefs.59 To support patients, they can be asked what is important to them, a question that has been
shown to extract the patients’ values.62

Patients should also be asked to express
any concerns they might have. The
physician should listen attentively and
respond to mistaken or incomplete information with a respectful explanation
of what is known and the crucial
distinction between documented and
theoretical risks. Making a recommendation, as explained below, may help to
allay the patients’ concerns.
The informed consent process should
be tailored speciﬁcally to each of the 3
groups of patients. For each, we identiﬁed the relevant clinical information and
how it should be evaluated by the
physician and, on this basis, how patients
should be empowered to make informed
decisions.
Counseling pregnant patients
The physician’s evaluation
When counseling patients, physicians
should use the available data to weigh the
beneﬁts of COVID-19 vaccines against the
risks.63 In evidence-based clinical judgment, the documented beneﬁts and risks
of COVID-19 vaccinations for use in
pregnant patients count more than the
theoretical risks and harms. The beneﬁt of
vaccination is prevention of COVID-19
infections and, consequently, the prevention of severe disease and mortality, and
prevention of the transmission of COVID19 to others. The risk of nonvaccination is
not only severe COVID-19 and increased
mortality, but also transmission of the virus to others. The complications of vaccinations for COVID-19 have been
documented to be rare and clinically
manageable. The fetal patient is not
exposed to the documented risk, based on

indirect evidence, nor is the breastfed
newborn.4,5,7 The mRNA strands are unlikely to cross the placenta and in mice
models, mRNA Zika virus vaccines have
been shown to protect the placenta.8 The
theoretical risks should not shape the
informed consent process and the physician’s evaluation that, when balanced,
COVID-19 vaccinations confer signiﬁcant
clinical beneﬁt. There is a consensus that
receiving a recommendation for a vaccination from a healthcare provider is the
most important factor in maternal
decision-making, irrespective of the
geographic or social context.64e68 It follows that the physician should recommend a COVID-19 vaccination as soon as
pregnant patients become eligible.
Empowering patients to make informed
decisions
The patient should be informed that when
COVID-19 occurs in pregnant patients, it
can be severe and life-threatening at levels
greater than those for nonpregnant patients. Vaccination has been demonstrated
to reduce the risk of infection and, with it,
the risk of serious disease and death. There
is a very low incidence of complications
following vaccination but these are transient and treatable. There is no evidence
for an increased risk associated with the
use of any nonliving virus vaccinations in
the fetal and neonatal patient.7 Patients
should be informed of available data63 and
be encouraged not to base their decisionmaking solely on theoretical risk. The
risk of complications, therefore, should be
considered alongside the very signiﬁcant
advantage of preventing infection, preventing asymptomatic infections and
potentially transmitting it to others, and
preventing serious disease, long-term
consequences, and death. For this reason,
the physician should explain why vaccination is recommended.
Counseling patients who are
breastfeeding or planning to breastfeed
The physician’s evaluation
There is no evidence that vaccines
contaminate breast milk. The biopsychosocial beneﬁts for the neonatal
patient are well established. SARS-CoV2 antibodies have been detected in the
breastmilk of infected patients and can
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potentially provide additional immunity
to the newborn. The beneﬁt of vaccination is unequivocal. Vaccination should
be recommended.
Empowering patients to make informed
decisions
The patient should be told that there is
no evidence of harm to her baby from
breastfeeding after receiving the vaccination and that there could be possible
beneﬁts for the newborn. Vaccination
should be recommended.
Counseling patients planning to
become pregnant
The physician’s evaluation
The patients’ information needs may
differ. Some patients planning to become
pregnant may be hesitant to accept
vaccination. The reasons for vaccine
hesitancy vary from person to person
and community to community. Others
may express concern or reject vaccinations based on false beliefs.
The physician’s response should be
professional, not personal. These patients should be treated with respect,
paying special attention to patients
inﬂuenced by false information that is
now circulating on internet sites, which
the patient may have visited or have been
told about by others. Physicians should
keep in mind that memory is created by
repetition, irrespective of whether that
which is repeated is true. This has the
important implication that the physician
should eschew prejudicial views about
patients who express false beliefs.
Instead, the physician should respond to
a patient in need, in this case, in need of
accurate information.
Other patients do not espouse false
beliefs but are prudent about being risk
averse with their planned pregnancies.
Prudence is a virtue that calls for a patient to identify her legitimate selfinterests, short-term and long-term,
and to act to protect them. Prudential
judgments should be evidence-based.
Current evidence supports the view
that legitimate self-interest in health and
life are supported by timely vaccinations.
The physician should point this out and
ask patients to reconsider their judgments. Research about previous
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pandemics has supported the healthcare
professional
recommendation
for
maternal vaccination as an important
factor that inﬂuences behavior.69
In ethical theory, patients who want
others to be vaccinated but not themselves
and who, therefore, want the beneﬁts of
herd immunity without vaccination are
known as “free riders.” This is a general
problem with vaccinations, including
childhood vaccinations.70 The decision to
be a free rider does not command respect
because free riders want others to take
risks without having to take those risks
themselves. The physician should point
this out and ask patients if they think that
this is fair to those who accept vaccinations. Allowing the patients to consider
this question empowers them to make an
informed and responsible decision.
There is no evidence that the vaccination affects present or future fertility
and the ASRM recommends that eligible
patients who are planning to become
pregnant should be vaccinated.46 Patients planning to become pregnant
typically do not want to impede their
fertility and want the best outcomes for
their pregnancies, both for themselves
and their babies. Having false beliefs is
incompatible with valuing these goals.
Empowering patients to make informed
decisions
The goal should be empowering patients
to recognize that they have mistakenly
adopted false beliefs that, if acted on,
would jeopardize their goals for their
planned pregnancy. For patients invoking
prudence, the physician should educate
them as described above. The goal should
be a patient who recognizes that her prudential judgment is not evidence-based.
For free riders, the physician should ask
them to reconsider as described above.
The goal should be a patient who understands that the responsible decision is
to become vaccinated.

When Patients Refuse Vaccination
Despite education, some patients, for
whom there are no contraindications for
vaccinations, will refuse the recommended vaccination. It is essential that
their refusal should not be taken
personally by the physician and that
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conversation with them should be
respectful.
This is especially important in
responding to decisions against vaccinations by patients of color. Their vaccine hesitancy or resistance may reﬂect
both a personal and community history
of mistreatment.
Patient refusal of COVID-19 vaccinations may be based on the fact that, as
the CDC has stated, “. . . there are
currently few data on the safety of
COVID-19 vaccines, including mRNA
vaccines, in pregnant people. . . .”1 and
based on the following statement by the
ACOG: “there are no safety data speciﬁc
to use in pregnancy.”2 This information
is being used in some countries to deny
pregnant women the opportunity to
accept vaccination (Table 1). No pregnant patient wants to do anything “unsafe.” When these statements are
repeated during a counseling session,
they may sound potentially scary, but
using the term “safety” is too nonspeciﬁc
as to what it means in the context of
COVID-19 vaccination in pregnancy.
The physician should put the absence
of safety data in pregnancy in its proper
perspective. We know that giving
COVID-19 vaccines to pregnant women
will be effective in preventing COVID-19
disease and that without the vaccine,
pregnant women are more likely to get
sick, be admitted to the ICU, and
possibly die if they become infected; that
adverse pregnancy outcomes, such as
premature births, are not more likely to
occur because of the vaccine; and that
the fetus is not more likely to have an
adverse outcome because of the vaccine.
ACOG states that “. . . pregnant patients who refuse the vaccine should be
supported in their decision.”2 This can
be read to suggest that the physician
should simply accept a patient’s refusal,
which is not an adequate response. The
physician has a strict legal obligation to
satisfy the requirements of what is
known as informed refusal.59 Patients
should be informed about the risks to
themselves and others when they are not
vaccinated. They are increasing their risk
of becoming infected and becoming sick
and infecting others, including their
newborn child. This disclosure should
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be documented in the patient’s record.
Meeting these requirements also protects
the physician’s legitimate interest in
reducing their liability. The ethics go
further and create an autonomy-based
ethical obligation to ask the patient to
reconsider her vaccine refusal, including
during any subsequent visits. During this
process, the physician should be alert
about vaccine hesitancy, ask patients to
express their hesitation and reasons for
it, and respectfully address them. For
patients who afﬁrm their vaccine refusal,
the physician should accept and respect
their refusal and offer an alternative of
enrollment in current clinical trials of
COVID-19 vaccines.

Conclusion
Evidence-based professional ethics in
obstetrics and gynecology provides unequivocal and clear guidance.59,60 There
is evidence that a healthcare provider’s
recommendation for vaccination is the
most important factor in maternal
decision-making,
irrespective
of
geographic or social context.64e69 Physicians should use available data to
weigh the beneﬁts against the risks of
COVID-19 vaccines63 and they should,
consequently, recommend COVID-19
vaccinations to all patients planning to
become pregnant, all pregnant patients,
and all patients who are breastfeeding
or planning to breastfeed. Instead of
using disease threat alone when recommending a vaccine, public health
campaigns, which center on the protectiveness and safety of a maternal
vaccine, may prove beneﬁcial.70 Minorities and especially African American patients continue to experience low
vaccination uptake rates, stemming, at
least in part, from years of bias in and
mistrust of orthodox medicine, safety
concerns, and environmental barriers to
vaccine access.71 To prevent the
widening health inequities, build trust
in the health beneﬁts of vaccination,
and encourage COVID-19 vaccine and
treatment uptake, in addition to recommending COVID-19 vaccinations,
physicians should engage with communities to tailor strategies to overcome
mistrust and deliver evidence-based

information, robust educational campaigns, and novel approaches to inﬂuenza immunization.71,72
Some statements from governments
and professional associations concerning
COVID-19 vaccinations implicitly adopt
the approach of shared decision-making,
a phrase often used without precision.
Shared decision-making means that the
physician should present information
but make no recommendation.73 This
assumes that shared decision-making, in
the sense of not making a recommendation, should guide counseling patients
about receiving COVID-19 vaccinations,
because of uncertain evidence about the
net clinical beneﬁt or risks of COVID-19
vaccinations. Shared decision-making in
this sense and without making a
recommendation should not guide
counseling of patients about COVID-19
vaccination who are pregnant, breastfeeding or planning to breastfeed, and
planning to become pregnant, because
recommending COVID-19 vaccinations,
we have shown, is justiﬁed on evidencebased and ethics-based grounds.
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